KCNA1-Related Episodic Ataxia and Epilepsy — an autosomal dominant episodic neurological disorder caused by heterozygous gain-of-function or dominant-negative pathogenic variants in KCNA1 (potassium voltage-gated channel subfamily A member 1 gene, chromosome 12p13); KCNA1 encodes Kv1.1, a voltage-gated delayed rectifier potassium channel expressed in axon initial segments, juxtaparanodal regions of myelinated axons, and presynaptic terminals of inhibitory interneurons; Kv1.1 channels contribute to repolarization of axonal action potentials and regulate neurotransmitter release from inhibitory interneurons — loss-of-function or dominant-negative KCNA1 variants impair Kv1.1 channel function, increasing neuronal and axonal excitability and producing a characteristic multi-system episodic neurological phenotype that includes: (1) Episodic Ataxia Type 1 (EA1) — the defining clinical feature: brief episodes lasting seconds to minutes of cerebellar ataxia with myokymia — spontaneous rippling of muscles visible under the skin, particularly around the eyes and at the corners of the mouth — a characteristic and nearly pathognomonic sign of KCNA1 disease; episodes are triggered by stress, startle, sudden movement, exercise, and temperature changes; interictal myokymia persists continuously between attacks and is clinically detectable even in attack-free periods; (2) Epilepsy — partial and focal seizures in approximately 20–30% of KCNA1 families, with temporal lobe epilepsy as the most common seizure type; (3) Neuromyotonia and cramping — persistent muscle stiffness, cramp-like sensations, and fasciculations from peripheral axonal hyperexcitability; the brevity and high frequency of EA1 episodes — seconds to minutes, distinguishing EA1 clearly from EA2 (CACNA1A), where episodes last hours to days — requires real-time episode diary platforms capable of capturing rapid-onset, short-duration attacks that patients may experience multiple times daily — as a condition at the intersection of episodic neurology, movement disorders, epileptology, and electromyography-guided neuromuscular medicine requiring multi-specialty care coordination.
KCNA1 care technology platforms — encompassing the molecular genetics laboratories where KCNA1 sequencing and deletion/duplication analysis establish variant identity and inheritance pattern; the episode diary platforms that are the primary outcome tracking tools for EA1 — where episode frequency, duration, severity, and trigger patterns must be documented in real time to assess carbamazepine or acetazolamide treatment response; the myokymia severity tracking systems documenting electromyographic and clinical observations of the characteristic interictal muscle rippling that distinguishes EA1 from other episodic ataxia forms; the carbamazepine and acetazolamide adherence and monitoring platforms coordinating drug level monitoring, hepatic function surveillance, and renal and metabolic monitoring for the two primary EA1 treatment agents; the epilepsy management portals tracking temporal lobe seizure diary records, AED adherence, and EEG surveillance for the minority of KCNA1 patients with concurrent epilepsy; the balance and gait rehabilitation scheduling platforms coordinating physiotherapy and vestibular rehabilitation between episodes; the trigger avoidance documentation systems tracking exercise intensity limits, temperature regulation compliance, and startle reduction strategy adherence; and the family cascade testing coordination systems for autosomal dominant KCNA1 disorder — where first-degree relatives have a 50% risk of the same condition and may be experiencing unrecognized episodic events — must maintain availability and performance standards matched to the episode diary urgency, carbamazepine monitoring requirements, and multi-specialty coordination demands of modern KCNA1 disorder management. This guide explains why KCNA1 care tech platforms need dedicated monitoring, what to monitor, and how to build a monitoring strategy matched to the real-time episode diary urgency and myokymia monitoring requirements of contemporary KCNA1 episodic ataxia care.
Why KCNA1-Related Episodic Ataxia Tech Platforms Require Specialized Monitoring Attention
KCNA1 episodic ataxia management is defined by several clinically urgent platform requirements: the episode diary urgency — EA1 episodes are brief (seconds to minutes) and may occur multiple times daily; real-time episode diary capture is essential because patients may not recall the precise frequency, duration, and trigger of brief motor events that occur many times between clinical visits, yet this data is the primary measure of carbamazepine treatment response and the determinant of dose optimization; the myokymia monitoring urgency — interictal myokymia is the pathognomonic sign of KCNA1 disease and is present continuously, not just during episodes; myokymia severity documentation — both clinical observation and electromyographic confirmation — provides the most reliable inter-visit monitoring metric for assessing disease activity and carbamazepine effect on peripheral axonal hyperexcitability; the carbamazepine monitoring urgency — carbamazepine suppresses myokymia and reduces EA1 episode frequency and is the preferred first-line treatment for KCNA1 EA1; carbamazepine requires hepatic function monitoring, CBC surveillance for aplastic anemia risk, and drug level monitoring, making laboratory platform availability during monitoring visits a treatment safety requirement; the epilepsy management urgency — 20–30% of KCNA1 patients develop concurrent temporal lobe epilepsy requiring AED management; carbamazepine's dual efficacy for both EA1 and temporal lobe epilepsy makes it a uniquely valuable drug in KCNA1 disease, but epilepsy management platforms must be accessible to coordinate the integrated treatment approach; and the trigger avoidance urgency — startle, exercise, temperature change, and stress are primary EA1 triggers; trigger avoidance diary documentation provides the basis for personalized trigger management counseling that reduces episode burden without medication dose escalation.
Molecular genetic testing platforms establish KCNA1 variant identity and guide treatment selection. Sequencing identifies pathogenic variants, establishes the dominant-negative or loss-of-function mechanism, and guides carbamazepine vs. acetazolamide selection. Monitor at 1-minute intervals during laboratory hours.
Episode diary platforms capture the high-frequency, brief ataxia events that are the primary EA1 outcome measure. Real-time documentation of ataxia episode onset, duration, severity, and trigger — potentially multiple times daily — requires continuous platform availability for accurate treatment response assessment. Monitor at 1-minute intervals during clinical hours.
Myokymia severity tracking platforms document the pathognomonic interictal sign that distinguishes EA1 from other episodic ataxias. Clinical and EMG myokymia severity documentation provides the inter-visit monitoring metric for carbamazepine effect. Monitor at 1-minute intervals during clinical hours.
Carbamazepine monitoring platforms coordinate the hepatic, hematological, and pharmacological surveillance required for EA1 treatment safety. Drug levels, CBC, and LFT monitoring at prescribed intervals require scheduling and result platform availability. Monitor at 1-minute intervals during clinical hours.
Epilepsy management portals coordinate temporal lobe seizure diary and AED monitoring for KCNA1 patients with concurrent epilepsy. Carbamazepine's dual indication for EA1 and epilepsy requires integrated management platform access. Monitor at 1-minute intervals during clinical hours.
What to Monitor on a KCNA1-Related Episodic Ataxia Tech Platform
Molecular Genetic Testing — KCNA1 Variant Identification
Monitor KCNA1 gene sequencing records (full coding sequence analysis — pathogenic variant identification; ACMG variant classification; missense variant localization — transmembrane domain, pore-forming loop, voltage sensor domain; dominant-negative vs. haploinsufficiency mechanism documentation — patch-clamp functional data; de novo vs. familial variant determination; large deletion and duplication analysis by MLPA or chromosomal microarray; variant registry cross-reference — published KCNA1 variants in EA1 mutation database and ClinVar; co-segregation analysis in multiplex families), genetic counseling records (autosomal dominant inheritance counseling — 50% offspring and first-degree relative risk; phenotypic variability counseling — same KCNA1 variant may produce variable episode frequency and severity across family members; myokymia as pathognomonic sign counseling — family cascade examination for myokymia; epilepsy risk counseling — 20–30% lifetime risk of temporal lobe epilepsy in KCNA1 families; reproductive options counseling; driving restriction counseling for active EA1 episodes), and family cascade testing coordination records (first-degree relative testing records; undiagnosed symptomatic family member identification records — EA1 misdiagnosed as anxiety-related dizziness, TIA, or panic attacks; pre-symptomatic testing records for at-risk relatives) at 1-minute intervals during laboratory hours. Alert immediately — KCNA1 molecular testing platform failures during evaluation of a 24-year-old man presenting with brief episodes of sudden-onset unsteadiness, slurred speech, and visual blurring lasting 15–30 seconds, occurring 3–5 times daily triggered by sudden noise or startling, accompanied by visible rippling of periorbital and perioral muscles between episodes — when KCNA1 sequencing identifying a pathogenic dominant-negative missense variant confirms EA1 with myokymia, initiates carbamazepine prescription that may substantially reduce episode frequency, triggers family cascade examination confirming his brother's similar episodes and visible myokymia as undiagnosed EA1, and avoids diagnostic pursuit of TIA or vestibular migraine that delays the correct diagnosis and effective treatment.
Episode Diary — EA1 Primary Outcome Monitoring
Monitor ataxia episode frequency and duration records (episode date and time — multiple daily events requiring time-stamped diary entries; episode duration — seconds to minutes characteristic of EA1 distinguishing from EA2 hours-to-days duration; episode onset acuity — sudden-onset fall vs. gradual unsteadiness; episode severity grading — mild gait unsteadiness vs. complete inability to stand; inter-episode return to baseline — full recovery between EA1 episodes; video capture records — brief smartphone video of episodes for clinical review), trigger documentation records (startle trigger records — acoustic startles, sudden tactile contact, unexpected stimuli; exercise trigger records — running, climbing stairs, sustained physical exertion; emotional stress trigger documentation; temperature change records — cold exposure, hot environments, fever; hunger and fatigue records; alcohol and caffeine records; specificity of triggers — personalized trigger sensitivity documentation), treatment response correlation records (episode frequency trend pre-treatment vs. on current carbamazepine dose; dose titration records and episode frequency response; breakthrough episode documentation on therapeutic carbamazepine levels; carbamazepine dose and episode frequency monthly trend; acetazolamide trial records for carbamazepine-intolerant patients — less consistently effective in KCNA1 than in EA2 but second-line option), and functional impact documentation (work and occupational impact of episodes — ability to drive or operate machinery; school impact records — attendance, examination performance; social and recreational impact; episode-related injury documentation — falls, cuts, concussion; falls risk assessment) at 1-minute intervals during clinical hours. Alert immediately — episode diary platform failures during a scheduled follow-up visit for a 31-year-old woman with confirmed KCNA1 EA1 who has been on carbamazepine for 4 months — when the episode diary platform withholding her 120-day diary reveals that episode frequency declined from 8–10 per day at baseline to 2–3 per day in months 1–2 on low-dose carbamazepine, then rebounded to 6–7 per day in months 3–4, a rebound pattern that with trigger diary review reveals a clear correlation with the patient beginning a high-intensity exercise training program 6 weeks ago — changing the clinical decision from carbamazepine dose escalation to personalized exercise intensity counseling combined with trigger avoidance strategy, preventing unnecessary medication increase and its associated dizziness and cognitive dulling side effects.
Myokymia Severity Assessment — Pathognomonic Sign Monitoring
Monitor clinical myokymia observation records (clinical examination records — periorbital myokymia documentation: rippling of orbicularis oculi visible at rest; perioral myokymia documentation: corner-of-mouth muscle rippling; limb myokymia records: undulating fascicular contractions; clinical severity grading — absent, mild, moderate, or marked myokymia; video documentation of myokymia for follow-up comparison; carbamazepine effect on clinical myokymia severity), electromyographic myokymia documentation records (EMG study records — myokymic discharge characterization: doublets, triplets, and multiplets firing at 2–60 Hz intervals; EMG amplitude documentation; muscle groups studied — orbicularis oculi, orbicularis oris, thenar muscles; EMG-to-clinical severity correlation; carbamazepine effect on myokymic discharge frequency and amplitude; baseline pre-treatment EMG records for treatment response comparison), and neuromyotonia and cramping diary records (muscle stiffness diary — continuous background stiffness between episodes; cramping frequency and distribution records; stiffness-to-cold exposure correlation; warm bath relief documentation — peripheral myotonia symptom pattern; pain diary for neuropathic and cramping pain; functional impact of background stiffness on grip and fine motor tasks) at 1-minute intervals during clinical hours.
Carbamazepine Adherence and Monitoring — EA1 Treatment Safety
Monitor carbamazepine adherence records (daily dose and schedule — carbamazepine immediate vs. extended-release formulation; dose titration records — starting dose and titration schedule; missed dose diary; serum carbamazepine level monitoring records — trough and peak levels; target therapeutic range documentation for EA1 vs. epilepsy dose ranges), carbamazepine safety laboratory records (CBC monitoring records at baseline and monthly for first 3 months, then annually — absolute neutrophil count, platelet count; aplastic anemia surveillance protocol records; hepatic function records — ALT, AST, bilirubin at baseline, 3 months, and annually; serum sodium monitoring — carbamazepine-induced hyponatremia surveillance particularly in elderly patients; HLA-B*1502 screening records — Stevens-Johnson syndrome risk in Han Chinese patients; Steven-Johnson syndrome documentation if reaction occurred), carbamazepine drug interaction records (carbamazepine enzyme induction effects — CYP3A4 induction; oral contraceptive interaction counseling for women of childbearing potential — carbamazepine may reduce oral contraceptive efficacy; carbamazepine interaction with other AEDs if concurrent epilepsy; carbamazepine interaction with antibiotics and antifungals; teratogenicity counseling documentation — carbamazepine neural tube defect risk), and carbamazepine side-effect diary records (dizziness and diplopia diary — dose-limiting vestibular and ocular side effects at high doses; drowsiness and cognitive dulling records; skin rash monitoring — maculopapular rash documentation; dose reduction records for intolerable side effects) at 1-minute intervals during clinical hours.
Acetazolamide Records — Second-Line EA1 Treatment
Monitor acetazolamide adherence and response records (acetazolamide dose and schedule for carbamazepine-intolerant KCNA1 EA1 — second-line agent; episode frequency response to acetazolamide — less consistent in KCNA1 than CACNA1A-EA2; acetazolamide vs. carbamazepine response comparison documentation; clinical trial or case series context — acetazolamide evidence base in KCNA1), acetazolamide safety records (serum bicarbonate monitoring — metabolic acidosis surveillance; renal function records — creatinine and eGFR; urinalysis and nephrolithiasis screening; paresthesia diary — dose-limiting tingling side effects), and 4-aminopyridine trial records where applicable (4-aminopyridine use in refractory EA1 — off-label; dose and response records; cardiovascular monitoring — QTc interval documentation; 4-AP vs. dalfampridine formulation records) at 1-minute intervals during clinical hours.
Epilepsy Management — Concurrent Temporal Lobe Epilepsy
Monitor temporal lobe seizure diary records (focal seizure documentation — déjà vu, epigastric rising, olfactory aura; secondarily generalized seizure records; seizure frequency and duration; nocturnal seizure records; post-ictal period documentation; seizure-free interval tracking for driving eligibility), AED adherence for epilepsy records (carbamazepine dose records noting dual indication — EA1 and temporal lobe epilepsy; additional AED records if carbamazepine monotherapy insufficient — levetiracetam, lacosamide; drug level monitoring; side-effect diary), EEG surveillance records (annual EEG scheduling; focal temporal lobe discharge documentation; ictal EEG records; video-EEG for seizure characterization; hippocampal MRI records — temporal lobe structural lesion exclusion; epilepsy surgery pre-surgical evaluation records for drug-resistant temporal lobe epilepsy), and driving restriction records for epilepsy (country-specific seizure-free period for driving; driving cessation and resumption records; occupational impact documentation) at 1-minute intervals during clinical hours.
Balance, Gait, and Rehabilitation — Inter-Episode Physiotherapy
Monitor physiotherapy scheduling and session records (vestibular rehabilitation records — vestibulo-ocular reflex training; balance and gait training records — Frenkel exercises, tandem walking; balance assessment records — Berg Balance Scale, Timed Up and Go; falls frequency and injury documentation; home exercise program records; fatigue management records — graduated exercise program to avoid exertional episode triggering), occupational therapy records (fine motor function assessment — grip, pinch strength affected by myotonia and cramping; workplace assessment records; adaptive equipment documentation; driving risk assessment — reaction time and coordination testing for driving eligibility), and physiotherapy records for neuromyotonia (stretching and muscle stiffness management records; hydrotherapy records — warm water exercise for myotonia relief; heat sensitivity assessment for exercise prescription safety; massage and physical modality records) at 1-minute intervals during clinical hours.
Trigger Avoidance Documentation — EA1 Episode Prevention
Monitor trigger identification and avoidance records (personalized trigger list documentation — startle, exercise type and intensity, temperature, stress; exercise intensity limit records — aerobic vs. anaerobic threshold documentation; startle reduction strategy records — noise-reduction headphones, environmental modification; temperature regulation records — cold avoidance, warm clothing; workplace accommodation records for startle-prone occupations), and family cascade testing and education records (first-degree relative examination records — myokymia presence, episodic symptoms; family member EA1 awareness education; caregiver training records — episode management, fall prevention during acute episode; school and employer awareness records — EA1 episode response plan) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. KCNA1 management coordinates across molecular genetics, neurology, neurophysiology/electromyography, physiotherapy, vestibular medicine, and epileptology — authentication failures block the multi-specialty team at encounters where episode diary records, myokymia EMG results, carbamazepine levels, CBC and LFT results, and seizure diary must all be simultaneously accessible.
SSL Certificates
Monitor SSL certificate expiry across all molecular testing platforms, episode diary portals, carbamazepine monitoring systems, myokymia tracking platforms, and epilepsy management portals. Certificate errors disrupting the episode diary during a period of treatment adjustment create documentation gaps for the primary outcome measure driving carbamazepine dose optimization.
HIPAA and Rare Disease Privacy Considerations for KCNA1-Related Episodic Ataxia
KCNA1 technology platforms handle molecular genetic records (KCNA1 pathogenic variant, inheritance pattern, family cascade testing implications), episode diary data (daily ataxia episode frequency with trigger identification), myokymia EMG records (electrophysiological evidence of axonal hyperexcitability), carbamazepine prescription and laboratory monitoring records, epilepsy and driving restriction records, balance rehabilitation documentation, and occupational impact records across affected individuals and at-risk family members.
Alerting Strategy for KCNA1-Related Episodic Ataxia Tech Platforms
Immediate laboratory-hours alerting for molecular genetic testing platforms: KCNA1 variant identification — the diagnosis establishing carbamazepine indication and epilepsy risk stratification.
Immediate clinical-hours alerting for episode diary platforms: Real-time ataxia episode counting and trigger documentation — the primary EA1 outcome measure driving carbamazepine dose optimization.
Immediate clinical-hours alerting for myokymia severity tracking platforms: Clinical and EMG myokymia documentation — the pathognomonic interictal sign and carbamazepine treatment response indicator.
Immediate clinical-hours alerting for carbamazepine monitoring platforms: Drug levels, CBC, and LFT records — safety requirements for EA1 treatment.
Immediate clinical-hours alerting for epilepsy management portals: Focal seizure diary and AED monitoring for concurrent temporal lobe epilepsy.
Sustained-failure alert (10–15 minutes): Balance rehabilitation, trigger avoidance, and family cascade testing records.
30-day advance warning: SSL certificates across all platforms.
Status Page for KCNA1 Care Team Communication
A real-time status page gives molecular genetics laboratories, neurologists and episodic ataxia specialists, neurophysiologists, physiotherapists, vestibular therapists, epileptologists, and rare disease registry coordinators immediate platform visibility without requiring inbound IT support contact during clinical hours.
Vigilmon Setup for KCNA1-Related Episodic Ataxia Tech Platforms
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | KCNA1 molecular testing and variant characterization | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling and family cascade testing records | 1 min | Slack + PagerDuty (lab hours) | | Episode diary portal — EA1 ataxia frequency and trigger | 1 min | Slack + PagerDuty (clinical hours) | | Myokymia clinical severity assessment records | 1 min | Slack + PagerDuty (clinical hours) | | Myokymia EMG documentation records | 1 min | Slack + PagerDuty (clinical hours) | | Neuromyotonia and cramping diary records | 1 min | Slack + PagerDuty (clinical hours) | | Carbamazepine blood level monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Carbamazepine CBC monitoring — aplastic anemia surveillance | 1 min | Slack + PagerDuty (clinical hours) | | Carbamazepine LFT and hepatic monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Acetazolamide adherence and metabolic monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Temporal lobe seizure diary (epilepsy subset) | 1 min | Slack + PagerDuty (clinical hours) | | EEG scheduling and temporal lobe discharge records | 1 min | Slack + PagerDuty (clinical hours) | | Trigger avoidance documentation records | 1 min | Slack + PagerDuty (clinical hours) | | Balance rehabilitation and physiotherapy records | 2 min | Slack (business hours) | | Driving restriction and seizure-free period records | 2 min | Slack (business hours) | | KCNA1 variant registry and research enrollment | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure KCNA1 molecular testing platforms with immediate laboratory-hours alerting
- Add episode diary portal with immediate clinical-hours alerting — real-time EA1 ataxia episode frequency and trigger documentation is the primary outcome measure
- Configure myokymia clinical severity records with immediate clinical-hours alerting — the pathognomonic interictal sign and carbamazepine response indicator
- Add myokymia EMG documentation with immediate clinical-hours alerting
- Configure carbamazepine blood level monitoring with immediate clinical-hours alerting — therapeutic range confirmation guides EA1 dose optimization
- Add carbamazepine CBC monitoring with immediate clinical-hours alerting — aplastic anemia surveillance is a treatment safety requirement
- Configure carbamazepine LFT monitoring with immediate clinical-hours alerting
- Add acetazolamide adherence and metabolic monitoring for carbamazepine-intolerant patients
- Configure temporal lobe seizure diary with immediate clinical-hours alerting for the epilepsy subset
- Add EEG scheduling with immediate clinical-hours alerting
- Configure trigger avoidance documentation with immediate clinical-hours alerting — personalized trigger management reduces episode burden
- Add balance rehabilitation and physiotherapy records with sustained-failure business-hours alerting
- Enable SSL certificate monitoring across all platforms
- Add the status page URL to KCNA1 neurology downtime protocols, EA1 episode diary procedures, and episodic ataxia clinic workflows
Conclusion
KCNA1-Related Episodic Ataxia technology platforms are embedded in clinical decisions where episode diary platform availability during a follow-up visit for a 28-year-old man with confirmed KCNA1 EA1 — when the neurologist must access the 90-day episode diary showing that episode frequency declined from 7–8 per day at baseline to 1–2 per day in the first 6 weeks on carbamazepine 200 mg twice daily, then plateaued at 3–4 per day in the subsequent 6 weeks with the trigger diary showing no new precipitants, a pattern that indicates partial but incomplete response requiring carbamazepine dose titration rather than medication switch — cannot be disrupted by episode diary platform failures that withhold the frequency trend at the clinical encounter where the dose titration decision is made; where carbamazepine CBC monitoring platform availability for results review at a scheduled monitoring visit — when the platform must deliver the CBC showing absolute neutrophil count declining to 1,400 cells/μL from 3,200 cells/μL at the 3-month check, representing early carbamazepine-induced neutropenia that requires immediate dose reduction, haematology consultation, and dose-range evaluation of the count trend to determine whether the drug can continue at a lower dose or must be discontinued — cannot be disrupted by laboratory monitoring platform failures that allow neutropenia to progress undetected through a missed CBC result review; and where myokymia EMG documentation platform availability for report access during a family cascade examination — when the neurologist evaluating a 22-year-old woman who is the asymptomatic sister of a confirmed KCNA1 EA1 patient must review the EMG report showing spontaneous myokymic discharges in periorbital and limb muscles confirming subclinical KCNA1 disease, establishing her diagnosis before she develops symptomatic episodic ataxia that might cause a fall while driving, and enabling prophylactic carbamazepine prescription — cannot be disrupted by EMG documentation platform failures that delay the at-risk family member's diagnosis.
Uptime monitoring gives KCNA1 care tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to molecular genetics laboratories, neurologists and episodic ataxia specialists, neurophysiologists, physiotherapists, epileptologists, and compliance auditors that platform operational reliability matches the real-time episode diary urgency, myokymia monitoring requirements, and multi-specialty coordination demands of modern KCNA1 episodic ataxia management.
Start monitoring your KCNA1 care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #KCNA1 #episodicataxia #EA1 #myokymia #Kv11 #potassiumchannel #voltagegatd #temporalobepilepsy #carbamazepine #acetazolamide #neuromyotonia #episodediary #trigger #startle #raredisease #channelopathy #epilepsy #HIPAA #healthtech #digitalhealth #uptime #sre